[Secondary immunodeficiency and its myelopid correction in patients with infiltrative and disseminated pulmonary tuberculosis].
The immunity of patients with infiltrative and disseminated pulmonary tuberculosis may be characterized as secondary immunodeficiency by the T-cell type and neutrophilic phagocytic activity. Myelopid has a stimulating effect on the humoral and cellular immunities, restores the baseline reduced functional parameters of neutrophilic activity.
Averchenkov
V M
VM
Lomachenkov
V D
VD
Fedotova
N I
NI
Meshkova
R Ia
RIa
D028341:Activins; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000995:Antitubercular Agents / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D007070:Immunoglobulin A / Q000276:immunology; D007074:Immunoglobulin G / Q000276:immunology; D007153:Immunologic Deficiency Syndromes / Q000209:etiology / Q000276:immunology / Q000628:therapy*; D008875:Middle Aged; D018375:Neutrophil Activation / Q000187:drug effects; D009842:Oligopeptides; D010455:Peptides / Q000627:therapeutic use*; D016896:Treatment Outcome; D014397:Tuberculosis, Pulmonary / Q000150:complications* / Q000188:drug therapy / Q000276:immunology
D000276:Adjuvants, Immunologic; D000995:Antitubercular Agents; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D009842:Oligopeptides; D010455:Peptides; C044147:activin B; D028341:Activins; C048617:myelopeptides
Vtorichnaia immunnaia nedostatochnost' i ee korrektsiia mielopidom u bol'nykh infil'trativnym i disseminirovannym tuberkulezom legkikh.